Your AI-Trained Oncology Knowledge Connection!
An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.
Joseph Unger, from the SWOG Statistical Center at the Fred Hutchinson Cancer Research Center, on Low-Income Clinical Trial Participation.
Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Abiraterone Acetate's Mechanism of Action
Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate
Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, on the Combination of Molecularly Targeted Therapies.
Dr. Roman Perez-Soler, from the Montefiore Medical Center, on the Correlation Between Erlotinib-Induced Skin Rash and Overall Survival
Dr. Axel Hauschild, from University Hospital, Schleswig-Holstein, Germany, Discusses the BREAK-3 Trial That Investigated the BRAF Inhibitor Dabrafenib.
Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial Coprimary Endpoints
Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer.
Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.
Dr. Richard Schilsky, from the University of Chicago, Summarizes the Recent Oncology Drug Shortage.
Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer
Dr. Dirk Arnold, from the University Cancer Center Hamburg, Germany, on Second-Line Bevacizumab Continuation Therapy for Metastatic Colorectal Cancer
Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.
Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.
Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.
Dr. Jorge Cortes, from the MD Anderson Cancer Center, Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial
Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial
Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education
Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.
Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate
Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial
Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia
Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.
Photos taken at the 2012 ASCO Annual Meeting held at the McCormick Place in Chicago, Illinois, from June 1-5, 2012.
Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.
The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.
The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.
Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.
Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.
